Sonoma Pharmaceuticals Inc. logo

SNOA

Sonoma Pharmaceuticals Inc. · NASDAQ

Website
Market cap
$4.5M

Sonoma Pharmaceuticals Inc. (SNOA) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for SNOA, including 2 SEC filings and 1 market update. The most recent was published Nov 13, 2026.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Financial highlights

Full financials
Revenue, TTM
$23.49M
Revenue growth
+38.7%
Net income, TTM
-$1.80M
Net margin
-7.6%
Free cash flow, TTM
-$2.79M
Cash
$4.61M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks23+50%
2026-05-24: 02026-05-31: 02026-06-07: 02026-06-14: 42026-06-21: 12026-06-28: 12026-07-05: 72026-07-12: 02026-07-19: 12026-07-26: 12026-08-02: 22026-08-09: 02026-08-16: 12026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 22026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 02026-11-08: 32026-11-15: 0
2026-05-242026-11-15
Mix690d
  • SEC Filings4(67%)
  • Other1(17%)
  • Market1(17%)
Activity · 52 weeks4727 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

SNOA FAQ

10 questions
  • What does Sonoma Pharmaceuticals Inc. do?
    Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the...
  • What is the latest news on SNOA?
    In the last 30 days Quantisnow tracked 3 wire items for SNOA: 2 SEC filings and 1 market update. The most recent was published on November 13, 2026.
  • What is SNOA revenue?
    Sonoma Pharmaceuticals Inc. (SNOA) reported $23.49M of revenue for the twelve months ended Sep 30, 2026. That is up 38.7% from the year before. Revenue for fiscal 2026 was $19.53M.
  • Is SNOA profitable?
    No. Sonoma Pharmaceuticals Inc. reported a net loss of $1.80M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does SNOA have?
    Sonoma Pharmaceuticals Inc. reported $4.61M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does SNOA stock trade?
    Sonoma Pharmaceuticals Inc. (SNOA) is listed on NASDAQ.
  • What sector and industry is SNOA in?
    Sonoma Pharmaceuticals Inc. operates in the Health Care sector, Medical/Dental Instruments industry.
  • When did Sonoma Pharmaceuticals Inc. go public?
    Sonoma Pharmaceuticals Inc. (SNOA) completed its IPO in 2007.
  • What companies are similar to SNOA?
    Notable peers in the same industry include ORGO (Organogenesis Holdings Inc.), IART (Integra LifeSciences Holdings Corporation), MDXG (MiMedx Group Inc), SNN (Smith & Nephew SNATS Inc.). Compare SNOA side-by-side with any of them on Quantisnow.
  • How can I track SNOA on Quantisnow?
    Quantisnow aggregates Sonoma Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNOA to receive live email and push alerts on every new disclosure.